Objective analysis INVION, page-2

  1. 72 Posts.
    Welcome to biotechs, where:

    * companies will not have any revenue or hope for revenue for many years
    * your hope is invested in intellectual property, and usually just a couple narrow pieces
    * companies raise just enough money to not dilute the heck out of themselves, but probably need to raise more to dilute themselves
    * the price is dependent on a few binary events

    Not many of the current buyers bought for the science. The science has not changed nor been proven a failure in the past year. People bought for other reasons, such as according to analysts who decided it was a buy at 10 cents, and a sell at 2 cents a couple months later (huh?!?). Unfortunately it's all driven by market sentiment and my sentiment does not change according to stock price unless the executives are all dumping. So I still stick by what I said a few months ago. It is a great risk to take at the 2.5 cent issue.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
11.5¢
Change
-0.010(8.00%)
Mkt cap ! $9.849M
Open High Low Value Volume
12.0¢ 12.0¢ 11.5¢ $6.561K 54.67K

Buyers (Bids)

No. Vol. Price($)
4 142313 11.5¢
 

Sellers (Offers)

Price($) Vol. No.
12.0¢ 43903 2
View Market Depth
Last trade - 11.39am 16/09/2025 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.